E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10024132 |
E.1.2 | Term | Leg spasticity |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary study objective is to assess the efficacy of Dysport compared to placebo at Week 4 on the change from baseline in the gastrocnemius-soleus complex (GSC) muscle tone (knee extended) in hemiparetic subjects with lower limb spasticity due to stroke or traumatic brain injury. |
|
E.2.2 | Secondary objectives of the trial |
The secondary study objectives will include assessments of the efficacy of Dysport compared to placebo on changes in the Physician’s Global Assessment (PGA) of treatment response and comfortable barefoot walking speed. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Provision of written informed consent prior to any study related procedures.
• Subjects with hemiparesis and between 18 and 80 years of age, inclusive.
• Subjects who had only one clinically defined stroke episode, as defined by the World Health Organisation (WHO) criteria or who have had one brain trauma.
• Toxin naïve subjects who have a MAS score ≥ 2 in the affected GSC (knee extended) or toxin non naïve subjects who have a MAS score ≥ 3 in the affected GSC (knee extended) at least four months after the last injection of BTX in the affected lower limb.
• Ambulatory subjects with spastic hemiparesis that causes a gait deficiency with a comfortable barefoot walking speed between 0.1m/s and 0.8m/s at baseline as measured on a 10 metre comfortable walking test without walking aids.
• Subjects who are at least 6 months post-stroke or post-brain trauma.
• Spasticity angle > 5° for the GSC of the affected leg as measured by the Tardieu scale (TS),(knee extended).
|
|
E.4 | Principal exclusion criteria |
• Major limitation in the passive range of motion at the affected hip, knee or ankle, as defined by:
o maximum passive hip flexion (knee flexed) < 30°,
o maximum passive knee flexion (hip flexed) < 70°
o maximum passive ankle dorsi-flexion (knee flexed)
<-10°
o maximum passive knee extension < 160°.
• Physiotherapy initiated less than 4 weeks before entry or expected to be initiated during the trial.
• Previous treatment with BTX of any type within four months prior to study entry for any condition.
• Subjects likely to be treated with BTX of any type in the upper limb during the course of this double blind study.
• Previous primary or secondary non responder to any Botulinum toxins for any condition.
• Previous surgery to treat spasticity of the affected lower limb.
• Previous treatment with phenol and/or alcohol in lower limb at any time before the study.
• Cognitive impairment altering the capacity to comply with the trial according to Investigator’s judgement.
• Severe neurological impairment (not associated with the stroke or brain trauma) due to an underlying neuromuscular disease or any other underlying disease or condition affecting gait (e.g. Multiple Sclerosis)
• Known disease of the neuromuscular junction (such as Lambert-Eaton disease or myasthenia gravis).
• Unwillingness or inability to comply with the protocol.
• Major hypoaesthesia or ataxia on the paretic side.
• Known sensitivity to BTX or any Dysport excipients.
• Infection at the injection site(s).
• Current or planned treatment with any drug that interferes either directly or indirectly with neuromuscular function (e.g. aminoglycosides) within the last 4 weeks prior to study treatment.
• Pregnant women, or pre-menopausal women not willing to use contraceptive measures throughout the duration of the study.
• Treatment with a new investigational drug within 4 weeks prior to enrolment into the study or scheduled treatment with such a drug during the study period.
• Any medical condition (or laboratory finding), that in the opinion of the Investigator may compromise compliance with the objectives and/or procedures of this protocol or preclude the administration of BTX.
• Subjects treated or likely to be treated with intrathecal baclofen during the course of the study or during the 4 weeks before study entry |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Mean change from baseline in the muscle tone measured in the GSC (knee extended) on the MAS |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Mean Physician’s Global Assessment Score
• Mean change from baseline in comfortable barefoot walking speed without walking aids |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 17 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Russian Federation |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 21 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 21 |